Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCS1 | P62166 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.57 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 9/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.44 |
| ▸ | FES | P07332 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.44 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.44 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19612122 | 0.92 | DYRK1A (0.57) | NCS1DYRK1ACSNK1DDCLK1FES | |
| SCHEMBL19612101 | 0.87 | DYRK1A (0.60) | NCS1DYRK1AAGPAT2CSNK1DUSP2 | |
| SCHEMBL19627274 | 0.84 | NPC1 (0.49) | NCS1CSNK1DDCLK1FESPIM1 | |
| SCHEMBL24044916 | 0.82 | DYRK1A (0.54) | NCS1DYRK1ACSNK1D | |
| SCHEMBL19612108 | 0.82 | DYRK1A (0.54) | NCS1DYRK1ACSNK1D | |
| SCHEMBL19612077 | 0.82 | NCS1 (0.45) | NCS1CSNK1DDCLK1FESPIM1 | |
| SCHEMBL19612128 | 0.82 | MAPT (0.44) | NCS1DCLK1FESPIM1CDK2 | |
| SCHEMBL19627267 | 0.81 | DYRK1A (0.53) | NCS1DYRK1ACSNK1D | |
| SCHEMBL19612166 | 0.81 | DYRK1A (0.53) | NCS1DYRK1ACSNK1DRXFP1KDM4E | |
| SCHEMBL19612165 | 0.81 | DYRK1A (0.53) | NCS1DYRK1ACSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-109415363-B | Novel mitochondrial uncoupling agents for the treatment of metabolic diseases and cancer | 罗格斯，新泽西州立大学 | 2021-07-20 | — | — | CN | disclosed |
| EP-3458454-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Rutgers, The State University of New Jersey (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | AK2, PC, GLS2 | NCS1 4216/4885DYRK1A 4412/4885AGPAT2 113/4885 |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | AK2, PC, GLS2 | NCS1 4028/4885DYRK1A 4289/4885AGPAT2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.